# Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects

> **NCT00126061** · PHASE3 · COMPLETED · sponsor: **Solvay Pharmaceuticals**

## Conditions studied

- Atrial Fibrillation
- Atrial Flutter

## Interventions

- **DRUG:** Tedisamil sesquifumarate

## Key facts

- **NCT ID:** NCT00126061
- **Lead sponsor:** Solvay Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** — (—)
- **Last updated:** 2015-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126061, "Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00126061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*